NCT07650513

Brief Summary

Prediabetes is associated with impaired fasting glucose and/or impaired glucose tolerance. Recent data indicate that more than one-third of adults in affluent countries have prediabetes . Fasting glucose concentrations of 100-125 mg/dL, hemoglobin A1c (HbA1c) titers of 5.7-6.4%, and two-hour post-stimulus glucose levels of 140-199 mg/dL are used to identify prediabetes. Behavioral lifestyle changes and medications are useful in preventing the progression of prediabetes to T2DM . Early detection and treatment of T2DM and prediabetes can prevent future health problems. However, many people with metabolic disorders are undiagnosed, partly due to the clinical practices and knowledge of primary care physicians (PCPs). PCPs play a critical role in diabetes prevention through the detection and management of prediabetes. Successful screening initiatives and the start of appropriate management interventions depend on PCPs' level of prediabetes knowledge Most patients with prediabetes do not receive evidence-based preventive care from their PCPs . Systemic barriers hinder physicians' ability to provide the best evidence-based practice, such as performance measures, insurance reimbursement, cultural expectations, and a lack of tools and staffing resources

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2026

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2026

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

June 10, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

June 16, 2026

Completed
14 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Completed
Last Updated

June 16, 2026

Status Verified

April 1, 2026

Enrollment Period

3 months

First QC Date

June 10, 2026

Last Update Submit

June 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Physician awareness of prediabetes risk factors, diagnostic criteria, and management recommendations

    Proportion of physicians who correctly identify: (1) risk factors for diabetes screening (e.g., age ≥35, BMI ≥25 kg/m², hypertension, family history of diabetes), (2) fasting glucose diagnostic cut-offs for prediabetes (100-125 mg/dL) and diabetes (≥126 mg/dL), (3) HbA1c cut-offs for prediabetes (5.7-6.4%) and diabetes (≥6.5%), (4) lifestyle modification recommendations for prediabetes (minimum 7% weight loss and 150 minutes of physical activity per week), and (5) appropriate use of metformin for prediabetes prevention.Validated structured self-administered questionnaire (adapted from Tseng et al., 2019) distributed via Google Forms, including multiple-choice and true/false questions

    Single time point during data collection period (April 1, 2026 to June 30, 2026)

Eligibility Criteria

Age25 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

physicians (faculty medical staff) at Sohag government hospitals and clinics, Egypt (target n=500, all specialties and training levels).

You may qualify if:

  • \- Physicians working at Sohag government hospitals and clinics
  • Faculty medical staff (any specialty)
  • Willing to complete the self-administered questionnaire
  • Provide informed written consent to participate in the study

You may not qualify if:

  • Physicians who decline to provide informed consent.
  • Physicians who do not complete at least 90% of the questionnaire items.
  • Physicians not actively practicing at a Sohag government hospital or clinic during the study period.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University Faculty of Medicine

Sohag, Egypt

Location

MeSH Terms

Conditions

Glucose Intolerance

Condition Hierarchy (Ancestors)

HyperglycemiaGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of internal medicine

Study Record Dates

First Submitted

June 10, 2026

First Posted

June 16, 2026

Study Start

April 1, 2026

Primary Completion

June 30, 2026

Study Completion

June 30, 2026

Last Updated

June 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations